A Phase 1 Study of LY3410738, a First-in-Class Covalent Inhibitor of Mutant IDH in Advanced Myeloid Malignancies (Trial in Progress)

被引：8
|
作者：
Stein, Eytan M.
Konopleva, Marina
Gilmour, Raymond
Szpurka, Anna M.
Hill, Elizabeth
Ward, Renee
Kantarjian, Hagop M.
Dinardo, Courtney D.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134307
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours
    Rodon, Jordi
    Argiles, Guillem
    Connolly, Roisin M.
    Vaishampayan, Ulka
    de Jonge, Maja
    Garralda, Elena
    Giannakis, Marios
    Smith, David C.
    Dobson, Jason R.
    McLaughlin, Margaret E.
    Seroutou, Abdelkader
    Ji, Yan
    Morawiak, Jennifer
    Moody, Susan E.
    Janku, Filip
    BRITISH JOURNAL OF CANCER, 2021, 125 (01) : 28 - 37
  • [42] A Phase 1 dose escalation study of TACH101, a first-in-class KDM4 inhibitor for advanced solid tumors
    Tsimberidou, Apostolia
    Vandross, Andrae L.
    Sommerhalder, David
    Joseph, Charmaine
    Chandhasin, Chandtip
    Perabo, Frank
    Clarke, Michael F.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [43] Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours
    Jordi Rodon
    Guillem Argilés
    Roisin M. Connolly
    Ulka Vaishampayan
    Maja de Jonge
    Elena Garralda
    Marios Giannakis
    David C. Smith
    Jason R. Dobson
    Margaret E. McLaughlin
    Abdelkader Seroutou
    Yan Ji
    Jennifer Morawiak
    Susan E. Moody
    Filip Janku
    British Journal of Cancer, 2021, 125 : 28 - 37
  • [44] Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer
    Jonker, Derek J.
    Laurie, Scott Andrew
    Cote, Gregory Michael
    Flaherty, Keith
    Fuchs, Charles S.
    Chugh, Rashmi
    Smith, David C.
    Edenfield, William Jeffery
    Conkling, Paul R.
    Mier, James Walter
    Goodwin, Rachel Anne
    Kwak, Eunice Lee
    Abrams, Thomas Adam
    Goel, Rakesh
    Cleary, James M.
    Li, Wei
    Li, Youzhi
    Jemison, Jamileh
    Hitron, Matthew
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors
    Do, Khanh T.
    Chow, Laura Quan Man
    Reckamp, Karen
    Sanborn, Rachel E.
    Burris, Howard
    Robert, Francisco
    Camidge, D. Ross
    Steuer, Conor E.
    Strickler, John H.
    Weise, Amy
    Specht, Jennifer M.
    Gutierrez, Martin
    Haughney, Peter
    Hengel, Shawna
    Derleth, Christina Louise
    Yap, Timothy A.
    ONCOLOGIST, 2021, 26 (11): : 925 - +
  • [46] A First-in-Human Phase 1 Study of Oral LOXO-338, a Selective BCL2 Inhibitor, in Patients with Advanced Hematologic Malignancies (Trial in Progress)
    Alencar, Alvaro J.
    Roeker, Lindsey E.
    Hoffman, Marc
    Murthy, Guru Subramanian Guru
    Patel, Vishalkumar
    Ku, Nora C.
    Pauff, James M.
    Eyre, Toby A.
    Jurczak, Wojciech
    Le Gouill, Steven
    BLOOD, 2021, 138
  • [47] A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress)
    Kumar, Shaji
    Kapoor, Prashant
    Alencar, Alvaro
    Murthy, Guru Subramanian Guru
    Hoffmann, Marc
    Pagel, John
    Patel, Vishalkumar
    Pauff, James
    Zinzani, Pier Luigi
    Le Gouill, Steven
    Mato, Anthony R.
    Jurczak, Wojciech
    Roeker, Lindsey E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S37 - S38
  • [48] A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress).
    Roeker, Lindsey Elizabeth
    Alencar, Alvaro Jose
    Murthy, Guru Subramanian Guru
    Hoffmann, Marc Steven
    Pagel, John M.
    Patel, Vishalkumar
    Pauff, James Michael
    Zinzani, Pier Luigi
    Le Gouill, Steven
    Mato, Anthony
    Jurczak, Wojciech
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax plus /- azacitidine in IDH1-mutated hematologic malignancies.
    Lachowiez, Curtis Andrew
    Borthakur, Gautam
    Loghavi, Sanam
    Zeng, Zhihong
    Kadia, Tapan M.
    Masarova, Lucia
    Takahashi, Koichi
    Tippett, George Dono
    Naqvi, Kiran
    Bose, Prithviraj
    Jabbour, Elias
    Ravandi, Farhad
    Daver, Naval Guastad
    Garcia-Manero, Guillermo
    Stoilova, Bilyana
    Vyas, Paresh
    Kantarjian, Hagop M.
    Konopleva, Marina
    Dinardo, Courtney Denton
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
    Razak, Albiruni R. Abdul
    Mau-Soerensen, Morten
    Gabrail, Nashat Y.
    Gerecitano, John F.
    Shields, Anthony F.
    Unger, Thaddeus J.
    Saint-Martin, Jean R.
    Carlson, Robert
    Landesman, Yosef
    McCauley, Dilara
    Rashal, Tami
    Lassen, Ulrik
    Kim, Richard
    Stayner, Lee-Anne
    Mirza, Mansoor R.
    Kauffman, Michael
    Shacham, Sharon
    Mahipal, Amit
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (34) : 4142 - +
12345